purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation azn earnings call period ending december image source motley fool astrazeneca plc azn q earnings callfeb etcontents prepared remark question answer call participant prepared remark andy barnett well warm welcome everybody astrazenecas fourthquarter fullyear result presentation conference call webcast investor analyst andy barnett head investor relation hand pascal member executive team would like cover important housekeeping point firstly probably sure realize material already website review forwardlooking statement would encourage take time read making comment performance using constant exchange rate cer core financial number nongaap measure nongaap gaap reconciliation contained within result announcement seen number quoted million yousshould invest astrazeneca plc right buy stock astrazeneca plc consider motley fool stock advisor analyst team identified believe best stock investor buy astrazeneca plc one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return february dollar unless otherwise stated slide show agenda today call following prepared remark open line question course want raise ask question room raise hand roving mics online please use zoom function raise hand usual try get many question course call limit number question ask give others fair chance participate pascal going hand pascal soriot chief executive officer thank andy good morning everybody welcome london stock exchange celebrating th anniversary company merging astra sweden zeneca uk quite number year ago want start talk slide slide important want recognize celebrate fact th anniversary importantly actually achieve goal set year ago reach billion sale fact could argue overachieved current exchange rate billion probably closer billion want say kind pat back even though would like celebrate team effort want mention always eye long term growth embarking another year cycle announced rd day want refresh strategy show planning next year got billion throw ups down say often lot skepticism always eye longterm growth rate going believe grow believe next year deliver superior growth course going drive profitability result growth sustainable strong growth really done whole following science embarking new cycle investing new science shape future medicine shape future company talk achieved whole discipline investment even though often extensive debate inside company challenging everybody even disciplined term investment constantly focused investment deliver growth also continuously focusing oncology cardiovascular disease respiratory disease recently increasing investment keeping eye immune disease finally rare disease company today team today different year ago really rewarding see progress made strength developed portfolio also strength talent company way operate oncology today different give confidence actually deliver another cycle strong growth next year importantly delivered upgraded guidance year growth excluding covid guided increasing low teen slightly better eps front grow also slightly better upgraded guidance year quarter four saw opportunity tax benefit saw opportunity invest drive growth stronger growth next year year launching new product expanding footprint saw emerging market china grew china rebounding growing china back growth trajectory year another good year improving operating margin see drop bit artifact driven large covid sale experienced course profit dilutes operating margin essentially see continuous progress wanted say today committed goal mids midterm course long term depending growth opportunity pipeline particular three thing said driving focusing today driving growth topline growth operating margin deliver financial goal really building pipeline continuously building pipeline drive growth investing new technology new product shape future medicine drive longterm growth call longterm growth often refer day tomorrow beyond ultimately goal remain highgrowth company next period time year beyond see revenue spread across variety therapy area oncology know well biopharma know well rare disease growth across crp area oncology cvrm ri course vi declined massive decline covid sale rare disease grew people expected actually expected remember guided could grow high single digit well business fact delivering low double digit goal right marc talk geography well yous emerging market ex china china see growing importance emerging market outside china europe grow established rest world japan starting impacted loss exclusivity nexium course still growth pretty nice number well diversified growth across geography across disease area two today tomorrow really pipeline pipeline guided earlier year goal new phase achieved shot three little bit delayed starting early instead large number start importantly potential blockbuster new product new indication blockbuster course billion phase trial successful deliver billion sale also achieve regulatory market regulatory approval across major market finally got approval four new medicine track deliver new molecular entity launch see see slide approval new medicine range biopharma airsupra oncology truqap back biopharm wainua eplontersen also rare disease alexion danicopan voydeya approval pnh across whole pipeline launching new medicine finally call day tomorrow really new technology new platform trying first believe tremendous opportunity leverage growing pipeline antibody drug conjugate io bispecifics adc space started collaboration daiichi sankyo know well built internal portfolio adcs adcs totally owned astrazeneca unique target unique warhead come talk later working multiple target warhead finally importantly combine bispecifics three two advanced exciting product believe oncology adc combination io totally transform way cancer treated position u one company potential leverage combination work cell therapy believe know cell therapy important technology future today mostly cart hematology want take solid tumor want take allergenic shelf cell therapy also want take immune disease started working leveraging internal effort internal technology combining way putting together series technology platform really potential u deliver talking moving solid tumor moving allergenic cell therapy moving immune disease complete set need question integration execution technology required achieve longterm goal cell therapy got listed neogen quell cellectis gracell together enable u build want oncology biopharm another technology believe shape longterm tcell engagers done internal effort complemented bd bd random bd always view build strong presence technology identified done dc cell therapy tcell engagers finally gene therapy focus rare disease rare disease really gene therapy approach complementing portfolio course know well pfizer gene therapy portfolio acquisition complemented cellectis collaboration really believe going drive little bit midterm growth daiichi sankyos collaboration adcs mostly looking driving growth beyond deliver growth today tomorrow day hand aradhana going take financials youaradhana sarin chief financial officer thank thank pascal usual start reported pl pascal mentioned opening comment total revenue increased top end updated guidance range product sale increased despite decline billion covid product sale year alliance revenue increased driven higher sale region daiichi sankyo book product sale turning core pl core product sale gross margin increased percentage point step gross margin driven lower covid revenue anticipate slightly lower product sale gross margin percentage driven higher sale emerging market increased beyfortus product supply higher production cost certain facility well higher product sale partnered product region book sale payout profit share partner cost sale core operating cost increased rd cost increased driven new phase start last year including multiple trial pd ctla bispecific volrustomig oral serd camizestrant rd cost percentage total revenue line ambition expected core sga stepped fourth quarter relative third quarter increased investment new launch behind wainua truqap airsupra continue invest behind indication expansion farxiga ckd heart failure imfinzi across tumor type fullyear core tax rate came slightly guidance fourth quarter tax rate benefited adjustment deferred tax following intragroup purchase certain intellectual property offset unfavorable tax ruling certain jurisdiction overall pl allowed u increase investment rd sga fourth quarter core eps full year growth versus prior year pascal stated earlier made good progress top bottomline delivery recent year remain track deliver industryleading growth improve operating margin mids midterm balanced need continued investment drive topline growth near term midterm long term today pleased announce fullyear guidance anticipate total revenue low double digit low teen percentage increase core eps low double digit low teen percentage increase well collaboration revenue expected increase substantially driven success based milestone certain anticipated transaction operating income hand anticipated decrease substantially recall included oneoff gain around million related renegotiated beyfortus agreement another million related sale inaudible yous fx rate february december remain average rate seen january anticipate low singledigit adverse fx impact revenue core eps cash flow operating activity increased million continue focus improving cash conversion already made significant progress area deal payment amounted approximately billion nearly half related past business development payment including milestone payment daiichi sankyo year anticipate billion deal payment relating historical transaction capex around billion anticipate significant step capex potentially range driven investment new manufacturing capability api inhaled product cell therapy net debt end billion given recent bd transaction totaling billion anticipate remain level mind finance expense expected increase given current interest rate environment net debt adjusted ebitda ratio time last month basis capital allocation priority remain unchanged number priority reinvest business pipeline behind new launch remain committed keeping strong investmentgrade rating continue pursue valueenhancing business development transaction towards end last year announced license agreement ecogen proposed acquisition icosavax gracell finally maintain progressive dividend policy defined either stable increasing dividend hand davedave fredrickson executive vice president oncology business thanks aradhana really appreciate oncology total revenue billion full year period grew versus prior year driven strong global demand key medicine tagrissos global revenue grew fourth quarter reflecting strong doubledigit growth yous europe performance quarter partially offset continued impact june mandatory price reduction japan well expected impact hospital ordering dynamic china rebate reclassification australia fourth quarter lynparza delivered product sale growth remains leading parp inhibitor globally despite ongoing class challenge period recognized million regulatory milestone merck following yous propel approval brcamutated prostate cancer imfinzi inclusive imjudo grew fourth quarter fueled global demand growth gastrointestinal tumor expect continued progress topaz himalaya although topaz demand yous moderate regimen established clear standard care japan price reduction based sale took effect february year additional mandatory price reduction anticipated later year based recent fixeddosing approval calquence total revenue increased fourth quarter driven continued new patient share gain across frontline relapsedrefractory cll total revenue million fourth quarter increased year year yous germany encouraged new patient share gain herpositive setting firmly establishing undisputed standard care across herpositive low metastatic breast cancer november last year received approval truqap novel akt inhibitor yous imfinzi topaz china importantly received priority review designation herexpressing tumor adjuvant use tagrisso added first time nrdl china discount exciting approval truqap opportunity extend leadership breast cancer including hormone receptor positive landscape established standard care lateline low look forward result destiny breast trial first half year opportunity bring line earlier expand ultralow tumor data tropionbrest trial datadx hormone receptor positive low breast cancer presented esmo last year presidential symposium discussion health authority prelaunch planning activity already well underway finally align ambition establish new endocrine therapy backbone several pivotal trial ongoing frontline nextgeneration oral serd camizestrant including combination cdk inhibitor truqap truqap well received clinical community united state already seeing rapid adoption majority new start patient biomarker altered tumor previously received cdk inhibitor consistent view addressable population see potential truqap become new standard care second line endocrine treated patient pikca akt p altered tumor advance next slide hand susan cover rd highlight quartersusan galbraith executive vice president oncology research development thank dave december entered definitive agreement acquire gracell technology furthers cell therapy ambition across oncology autoimmune disease gracell proprietary cell therapy manufacturing platform called fastcar fastcar platform several key benefit first significantly reduces manufacturing time week hour opportunity improve medium turnaround time also enable increased manufacturing capacity well predictability cart delivery second lower dose cell need manufactured patient reduces risk cytokine release syndrome improve safety profile third shorter manufacturing time delivers fitter tcells potentially improves efficacy cart proposed acquisition also enriches growing pipeline cell therapy gcf novel clinicalstage dual bcma cd targeting autologous cart phase data presented ash meeting december patient newly diagnosed highrisk multiple myeloma objective response rate saw minimal residual disease negativity rate month infusion demonstrates promise potential therapy move earlier line setting safety also favorable patient experiencing either grade cytokine release syndrome grade event additionally see neurological toxicity associated type therapy median followup time month median pfs median duration response reached also highlighting durability response believe gcf potential application across hematologic malignancy including multiple myeloma bolster hematology pipeline adding calquence azd cd cd nextgeneration bispecific cell engager azd gprcd targeting antibody drug conjugate also two homegrown hematology molecule entered clinic cd antibody drug conjugate asd prmt inhibitor azd look forward updating exciting hematology pipeline course year please advance next slide pas ruud cover biopharmaceuticals performanceruud dobber executive vice president president biopharmaceuticals thank much susan biopharmaceuticals delivered total revenue billion driven growth crm rni key highlight year included farxiga nearing billion total revenue ri returning doubledigit growth turning fourth quarter within ri nearly half total revenue came fasenra despres sanalla breztri medicine grew combined offsetting impact symbicort generic entry vi beyfortus continued see strong demand first rsv season generating million product sale alliance revenue astrazeneca quarter lastly received first sale related milestone payment sanofi totaling million recently launched three innovative new medicine within biopharmaceuticals launch new area science medicine require u raise awareness among patient practitioner often build additional sale force maximizing early momentum launch brand critical delivering full potential eplontersen amyloidosis treatment developing partnership ionis january launched brandnew wainua patient attr polyneuropathy debilitating ultrarare disease generally fatal within decade left untreated airsupra first rescue medicine reduce exacerbation treat underlying inflammation shown mandela trial reduction risk severe asthma exacerbation adult patient compared albuterol formally launched airsupra last month adult patient time hope see primary care physician united state changed year prescribing habit mentioned strong start halfway first rsv season beyfortus available infant following continued strong demand recent approval china planning substantial increase capacity continue invest behind farxiga brand growth driven across global across globe recent launch heart failure chronic kidney disease coming year aim continue build franchise new combination medicine development address unmet need hypertension heart failure ckd additional enemy latestage early stage pipeline cvrm portfolio set expand evolve midto long term recently commenced phase trial baxdrostat uncontrolled resistant hypertension well zibotentan combined dapagliflozin addressing patient ckd high proteinuria eplontersen also evaluated treatment attr cardiomyopathy estimated affect million patient worldwide phase cardio transform trial largest kind powered show cardiovascular mortality benefit pleased share today obtained fast track designation fda cardiomyopathy regulatory file hand sharon present latest development biopharma pipelinesharon barr executive vice president biopharmaceuticals research development thank much ruud wanted take opportunity highlight current portfolio immunology well provide color recent business development deal focused immunemediated disease saphnelos pivotal phase litcells systemic lucerathermatosis saw positive change cutaneous lupus building expanding new indication started enrolling patient phase daisy trial saphnelo patient systemic sclerosis chronic disease characterized diffuse fibrosis vascular abnormality skin joint internal organ fatal also plan initiate saphnelo phase trial year cutaneous lupus myositis recent business development deal accelerated ambition immunemediated disease emerging data dr seth academic group shown potential longterm remission cart systemic lupus erythematosus part definitive agreement acquire gracell includes autologous cart ongoing phase investigatorinitiated trial gc cd bcma cart chinese patient sla look forward sharing phase data upcoming conference collaboration quell designed develop multiple engineered tregulatory cell therapy potential transformative type diabetes inflammatory bowel disease treg cell therapy unique approach modulating immune system reduce inflammation prevent immunemediated damage tissue quells innovative platform armored tregs could enable sustained clinical benefit finally collaboration cellectis allows u explore potential allogeneic cart platform offtheshelf availability allogeneic cart cell expected reduce time cost associated manufacturing innovative transformational cell therapy well internal capability building platform pipeline immunemediated disease transformative potential hand marc cover rare disease portfoliomarc dunoyer chief executive officer alexion chief strategy officer astrazeneca thank sharon rare disease total revenue achieved billion year year driven growth neurology indication increased patient demand launch new market quarter ultomiris grew plus full year driven knowledge indication vast majority growth coming generalized mastenagravis patient naive branded treatment previously indicated ultomiris revenue broadly line soliris year look fourth quarter ultomiris revenue exceeded soliris conversion strategy progressing well majority patient already converted across phn atypical haemolytic uraemic syndrome gmg major market continue launch medicine globally expect cfi franchise soliris ultomiris revenue remain sustainable durable beyond complement strensiq koselugo grew respectively driven continued patient demand also delighted announce started enrolling patient phase trial translating amyloid cardiomyopathy well hypophosphatasia alexion monoclonal antibody designed deplete toxic amyloid fibril heart potential treat ttr cardiomyopathy combination standard care stabilizes silence phase trial recruiting broad range patient moderate severe disease designed hard cardiovascular endpoint allbecause mortality cardiovascular event extremely important patient clinician well regulator payer begun enrollment phase program fortis alpha hypophosphatasia including two trial pediatric setting investing naive switch patient well larger trial naive adult adolescent trial represent broad set hypophosphatasia patient including skeletal functional improvement believe product every twoweek dosing lower volume injection coupled improved manufacturing creates significant opportunity increase addressable population three time compared strensiq made great progress latestage pipeline nine phase program underway th program ultomiris igan initiating soon please announce get pascalpascal soriot chief executive officer thank marc move last slide really show next month quite number catalyst going drive u across oncology biopharm also rare disease listed course number missing also flora deliver updated o data course important going drive growth several important product lora tagrisso destine driving tropion breast exit waypoint study studying tezepelumab chronic cynositis nasolpolyps finally inaudible imfinzi course lot point wanted make conclusion midterm pipeline actually emerging rapidly good data coming bispecifics portfolio data point communicated course year adcs data also share adcs pipeline shaping emerging metabolism portfolio talk much yet actually progressing nicely exciting pcsk making good progress baxostat hypertension phase finally course oral glp agent license sale beauty agent combined combined adc come combine metabolism portfolio really starting take good shape beyond product mentioned come course obesity also cardiovascular heart disease renal disease cell therapy year communicate mid stage study progression finally also communicating information new dda pipeline particular parp selective see quite lot new data coming phase pipeline also midstage pipeline give sense coming believe excited believe continue drive top line growth next year drive improvement profitability result finally want invite rd day cambridge disc new rd center see join u st may see fantastic site team excited sure drive momentum rd productivity reason rd day said completed year journey started engaging next phase ourin next year thought good time sit back update strategy show confident future bright astrazeneca stop open floor questionsjames gordon jpmorgan chase company analyst thank james gordon jp morgan two question please first one revenue year guidance low doubledigit low teen revenue target think bear worried lot collaboration revenue growing product sale slowing say fair also think sustain sort pace product sale growth really collaboration revenue taking product sale first question please think second question thing somebody said today topline guidance pace bottomline guidance would imply margin might flat seen think slide said mediumterm margin get mids mean margin flat year big inflection get thought whether going lot opex going work pleasepascal soriot chief executive officer thank james great question open floor sure let categorical product sale going grow strongly collaboration revenue course adding growth certainly product sale much track deliver kind growth included guidance range communicatingaradhana sarin chief financial officer yes mean look example growth across franchise right oncology growing rare disease cvrm current product expect momentum continue coming year obviously different product different sort dynamic forth growth come product sale current product well new launch though early launch trajectory think second question given obviously range top line bottom line element mentioned prepared remark one example finance expense expect slightly go given transaction toward end last year forth refinancing debt second element obviously benefited little bit tax rate last year tax rate benefit also look totality pl also element get range eps take account obviously expect revenue growth pretty strong operating expense growth lagging revenue growth operating leverageemily field barclays analyst hi emily field barclays couple question oncology first dax dxc avanzar study must enrolled pretty quickly readout positive would file based study know designed somewhat differently tl destiny brest much inclusion ultralow population expand addressable patient set think said low breast cancer much bigger get ultralowpascal soriot chief executive officer susansusan galbraith executive vice president oncology research development yes avanzar yes accrual gone well think demonstrates interest potential data combination particular data dxd plus immune checkpoint inhibition know seen exciting data couple different setting tropion lung data set well begonia study triplenegative breast cancer think investigator interested potential improve outcome patient firstline nonsmall cell lung cancerpascal soriot chief executive officer study progressing quickly recruitment pointed second dbo low may davedave fredrickson executive vice president oncology business yes thanks emily question think two thing think important dbo first one expands opportunity positive like highlighted move ultralow specifically question lay look hormone receptor positive metastatic breast cancer within ihc low covered db got estimate zero one category much add within got true zero first expansion outside ultralows also moving line earlier moving line earlier two opportunity see growth data dependent one course longer duration therapy would hope get move earlier data really compelling could see put pressure see lot endocrine recycling take place within patient data dependent see magnitude benefit three different opportunity contribute growth moving forwardmatt weston ubs analyst matthew weston ubs two question first one stick well think q yous sale probably little bit light term growth people expecting daiichi reported total enduser sale time think daiichi commented penetration reaching plateau yous market data expansion coming going much opportunity think lot investor felt low significantly bigger suggesting already plateaued would love understand happening also dave touch pan tumor seems fly radar may actually quite significant indication rather second question added guidance essentially pointing onetime asset sale something take account remember quite time suggesting might significant size way help frame itdave fredrickson executive vice president oncology business want start matthew made comment prepared remark think important piece commenting quarter past found hit really kind threshold running herpositive low knew opportunity drive continued growth beyond really pleased see really pleased see putting effort promotional effort within yous large market within europe done conjunction truqap launch really make sure got promotional muscle need seeing movement herpositive new patient start moving right direction going right level think basically matthew think happened replaced lot almost kadcyla use moving harder yard getting traction turn low herlow opportunity continued growth beyond gotten many respect complicated discussion able talking multiple therapeutic alternative exist within hormone receptor positive space obviously working testing effort though think got optimism got opportunity continue grow think lot growth front still yous still europe think emily asked would tailwind add thatmatt weston ubs analyst pam tumordave fredrickson executive vice president oncology business pam tumor pam tumor spot right got breakthrough therapy designation later line highest expressors think take look population got several thousand patient across multiple tumor type could addressable early label might relatively modest compared example opportunity think evidence generation take place continue work space demonstrate lower level expression think pan tumor exactly third leg stool susan talking add herpositive breast low good growth driver midterm herpascal soriot chief executive officer aradhana want take aradhana sarin chief financial officer talked income expect decline substantially last year remember two particular transaction contributed large amount signaled asset sale expect collaboration revenue increase substantially talked milestone potential transaction contemplating position give detail today see year unfoldsdave fredrickson executive vice president oncology business pascal super briefly one thing forgot mention nccn guideline included endometrial cervical ovarian within population got priority review think acknowledgment clinical community seeing benefit studyandrew baum citi analyst thank andrew baum citi staying pam tumor trial low part trial clear signal many malignancy active obviously manufacturing derisked question leaving money table seeking expedite development individual low indication look like going get approval per pantumor low going need set trial competitor asset initiated trial herlow setting left white space competitor come got asset could monetizing setting second question relation truqap curious think enabolosib data going impact use truqap given hitting pikakt pathwaysusan galbraith executive vice president oncology research development yes white space question got brand like really exceptional activity across think philosophy make sure develop maximum potential everything planning currently visible would expect see trial think build actually seen pantumor think creates lot opportunity intend leave little white space possiblepascal soriot chief executive officer term susan galbraith executive vice president oncology research development want address market size thisdave fredrickson executive vice president oncology business yes sure mean look think would comment andrew seeing positive receptivity truqap seen strong uptake term number new patient started therapy actually hearing awful lot desire among community seen broader label based upon data set presented seen obviously within context competitive landscape truqap data ultimately looked within context think really showing favorably within context anticipate continue strong launch medicine year look forward additional life cycle readout going heel obviously susan galbraith executive vice president oncology research development opportunity would say capivasertib combination also remember treat broader group patient look alpha mutant group got pan got akt activation well multiple way different think firstline space also something interestdave fredrickson executive vice president oncology business andrew mean think pace maybe skipped thought kind without saying truqap post cdk invotas looking different population different spotssusan galbraith executive vice president oncology research development different population taking firstline setting fast progress even take population went look first line completely lack invoice patient population clearpeter welford jefferies analyst peter welford jefferies two question sticking norm first question investor event st may think called rd event guess curious outline going de much focused midterm pipeline also giving year vision going year vision setting another year revenue aim guess sort granularity anticipate look forward going set aim next period second one airsupra mentioned obviously much year building access building awareness building guess curious comment made think time expect yous pcp change year habit mean sound still lot slog go talk debate discussion gone successful barrier doctor year got anything model another year really thinking action set comepascal soriot chief executive officer two great question peter let cover first one ruud could cover airsupra rd day really want explained earlier explain strategy think grow strongly next year course going look midterm pipeline also want look investment making new technology new platform actually deliver growth beyond actually give good understanding near term also midterm long term relates whether going set longterm revenue ambition may decided tell confident actually grow strongly next year work issue mentioned instance medicare part reform work end impact relatively limited hesitate use word margin quite limited context global sale walk work patent expiry limited continue deliver strong growth course going gross number every year look next five year year suddenly grow actually want hopefully convince share strategy see whether come number notruud dobber executive vice president president biopharmaceuticals yes let first rearticulate let u say excitement regarding airsupra first substantial market united state alone roughly million million script cobiterol asthma indication said started journey order gain access last year good news formulary listing three largest commercial pbms based registration late order get part bidding part course hopefully create access moving forward many patient anyway commercial younger patient seen first week still early day nice number trialists already thousand gps also specialist prescribing airsupra said axis still let u say issue working need buy script course per script quite substantially clear star strong start united state equally course take time get enough access order switch conversion hence sale follow le pattern seen breast seen announcement braceras growing way become blockbuster hopefully soon think expecting pattern also airsupra moving forwardpascal soriot chief executive officer think really important point ruud said really expect oncology new indication really address big unmet need fast sale ramp progressive beauty kind inhaled product established durable asset mean look symbicort around long long time still still good product good sale good profitability resilience get right level stay good level long time come huge amount competition clear unmet need theremark purcell morgan stanley analyst mark purcell morgan stanley thank two question first one aradhana guess people concerned morning certain anticipated transaction part cr guidance expect increase substantially guess triangulate part selected moving forward last time move forward parp inhibitor billion milestone partner confirm rd potential revenue still low presume importantly could give u qualitative guidance sga obviously stepped lot q land fullyear second question ckm syndrome pipeline guess going symptomatic disease like obesity reserved election heart failure capture asthmatic disease like ckd could help u understand opportunity level investment going put behind combination asset franchise specifically ecogen drug getting lot question around manufacturing help u understand many cmc step product given orphagen estimated therefore incredibly difficult scale thank youaradhana sarin chief financial officer sure sga front look fourth quarter last year think mentioned concern term stepup look last several year fourth quarter always largest quarter term sga mean run rate sort obviously going forward look updated guidance tax transaction net tax change mind manage whole pl chose invest certain area including launch heard rod forth sort explained fourth quarter think looking obviously given guidance top line bottom line talked increase finance expense talked little bit gross margin expectation sort consider see sga growth obviously committed operating leverage expect given put take sga growth lower total revenue growthpascal soriot chief executive officer maybe add understand question also concern mentioned connecting james earlier question think important keep mind believe product sale guidance potash grow strongly mean guidance low double digit low teen right range product sale range message top line revenue growth driven mean dependent oneoff saidruud dobber executive vice president president biopharmaceuticals yes let first phase opportunity ckd market million patient around world suffering ckd despite progress seen last year especially sglt class including farxiga still huge unmet medical need hence let u say excitement also product development clearly one combination dapagliflozin placebo tenant course sharon talk well make u quite bullish opportunity equally mark developing legion potential egan molecule space many company left field kidney space believe huge opportunity based pipeline order really build strong pipeline know whether want talk little bit one combination sharonsharon barr executive vice president biopharmaceuticals research development asked u scope investment also address question space focus metabolism reframe ruud said million people living ckd hypertension yous alone clearly large market speaks interrelatedness cardio renal cardiometabolic disease thinking address different flavor ckd portfolio advancing baxtrodapa combination phase ckd boston renan combined dapagliflozin miracle phase study ckd heart failure achieved highlevel result end last year really look forward sharing upcoming conference deck phase planning point combination zibotentan dapagliflozin allows u address ckd high proteinuria initiated zenith phase trial clearly heavily invested space view opportunity manage complexity cardiorenal disease help people manage overall health mind think metabolism portfolio dovetail nicely effort dive organ protection managing health understand disease highly interconnected think million people heart failure worldwide million alone europe europe alone know patient renal impairment interrelated metabolic disease make sense want continue expand portfolio metabolism space think open acquisition interest program also program one piece overall focus metabolic disease moving along pace also longacting amylin well glp glucagon dual agonist speaking briefly excited asset encouraged see move forward two phase b trial yearpascal soriot chief executive officer want say word manufacturing stepssusan galbraith executive vice president oncology research development actually say two thing first one key focus able simplify manufacturing process come simpler synthetic route together collaborator epogen think making substantial progress front second thing say continues speak interconnectedness disease orally bioavailable molecule well suited potential combination oral molecule portfolio would include list farxiga well oral pcsk inhibitor look forward sharing result phase trial recently wrapped highly controlled fourweek inpatient trial piloted ecogen achieved database lock end december look forward sharing data upcoming medical conferencepascal soriot chief executive officer maybe one quick point every focus obesity big segment people abused overweight need lose weight need lose bit weight metabolic disease sometimes organ damage well segment extremely large payer likely pay managing various dimension metabolic syndrome pcsk apa bacostat able combine going substantial advantage portfolio insimon baker redburn partner analyst simon baker redburn atlantic two please firstly inaudible saphnelo market wonder could give u update characteristic prescribers patient far drug question gracell fastcar could give u idea easily scalable manufacturing technology also bit color comment gracell made past substantial manufacturing cost advantage sound like could quite significant move autoimmune area color would much appreciated thank youruud dobber executive vice president president biopharmaceuticals yes let first start question test product well united state also equally market launched leading nbrx newtobrand market share country like spain germany patient population interesting one primarily patient let u say moderate normal full count allergic low patient population highly dominant see far equally also know clinical study inaudible also well established high ease fill united state broad utility product need biomarker need phenotyping make highly attractive choice especially alges pulmonologists well high expectation together partner think fair say product way become blockbuster anytime soon one saphnelo another nice story interferon receptor antagonist know lupus disease multiple manifestation multiple organ manifestation particularly impactful skin disease seen strong feedback rheumatologist patient primarily skin manifestation reacting well safanella equally operating intra market speak last one half two year relatively large study subcutaneous formulation truly believe hopefully next year study read positive readout provide another clear opportunity sharon mentioned remark keen move safanella also multiple indication order grow brand also equally blockbuster brand next yearspascal soriot chief executive officer thanks rudd want comment gracellsusan galbraith executive vice president oncology research development mentioned prepared remark actual time need manufacture fasco substantially shorter currently commercially available car therapy one component turnaround time obviously one component also manufacturing cost think help scalability amount time need process individual patient batch also shorter within manufacturing facility mean get increased capacity given manufacturing building created important also mean predictable delivery actually generating smaller total number cell delivered patient likelihood success higher thing think contribute overall benefit see fasco processpascal soriot chief executive officer thanks susan maybe could take one online question tim anderson wolfe research tim youtim anderson wolfe research analyst thank headwind revenue growth individual key brand would like call relative see consensus rare disease facing new competition oncology talked tagrisso calquence yous seems stalling example second question dato risk approval yous lung nonsquamous based today regulatory precedent low risk get approved necessarily consensus view confidence happens o miss bond squamous remain supportive formally hitpascal soriot chief executive officer thanks tim proposed marc cover general competitive environment dave could cover calquence tagrisso tagrisso maybe also talk headwind also potential upside susan cover toomarc dunoyer chief executive officer alexion chief strategy officer astrazeneca let start basically headwind anticipate introduction biosimilars pnh indication two competitor started gain approval impact still limited obviously could increase time way counteract headwind converting fast possible soliris ultomiris main indication neurology indication well ph conversion high magnitude first thing also sustaining growth complement franchise buying expanding regional presence augmented significantly still work increasing number approval reimbursement soliris well ultomiris lastly longterm work make franchise sustainable continuing develop new indication approved recently europe japan rapid uptake soon get yous approval also continue indication presently phase c also want nanobody bispecific givilimab well advanced phase coming market soon future bright future c franchise complement franchise overalldave fredrickson executive vice president oncology business turning oncology tim question directly first question place headwind relative consensus commented prepared remark one would call think important japan february repricing imfinzi sure built model moving ahead anticipate change weightbased fixed dosing see another japan imfinzi price adjustment said specific question tagrisso enthusiastic tagrisso end year come next year mentioned seeing good underlying demand growth sequentially within yous within europe think coming heel adaura flaura performing well got opportunity china despite competition seeing move anticorruption shadow think affected ability able really take advantage leadership position right thing term access general oncologist limited got flaura knock wood see approval sometime within year got laura think really important catalyst read within first half look outset think also competitive landscape basis flaura position u pretty nicely calquence question got competitive environment got direct competition also like yous european team able face stack competition think within got leadership position within frontline cll able maintain think take month quarterly phasing situation seen really good strong underlying demand growth calquence throughout entirety year hopeful optimistic copay within yous lowered pascal talked remark see affordability go patient pay catastrophic therefore copay cap going give patient ability able stay greater adherence continuous treatment progression btk therapy see play see work think element give enthusiasm oncology portfolio opportunity front uspascal soriot chief executive officer think copays really underestimated look yous system medicare side going good system mean many country copays mean australia copay many country copays united state people patient going able say going pay year regardless many drug received regardless much cost might say fair amount money car insurance house insurance going cost least many people afford great level reassurance term taking medicine adherent u mean reduction free good give increasing substantially last year people people afford cover copaysluisa hector berenberg capital market analyst thank luisa hector berenberg question dato susan galbraith executive vice president oncology research development first thanks question confident dato going important medicine treatment nonsmall cell lung cancer obviously ongoing discussion regulatory authority tl trial dual primary end point obviously met pfs one primary o going important second third line setting think historically checkpoint inhibitor medicine demonstrated o benefit tax currently remains standard care remind nonsquamous population data presented asco showed hazard ratio nonsquamous o confidence interval overlapped upper end think show seeing progressionfree survival benefit strong trend o within patient population quite often normal o event mature often update o period review would anticipate period review tll update osluisa hector berenberg capital market analyst thank luisa berenberg would like ask iskra reic comment icosavax deal attraction asset opportunity enter rv market also maybe pillar slightly bigger picture question essentially margin question sorry shown u fabulous pipeline progress breadth depth see entry new therapeutic area modality vaccine cell therapy et cetera really bubbling really confident margin expansion midterm happen point selling cost infrastructure stabilizes fabulous product compete rd budget strict almost attrition making sure absolutely best project moving forward color give u confidence ability raise margin given excitement within pipeline thank youiskra reic executive vice president vaccine immune therapy thanks luisa question interest really strengthened vaccine cost lead asset combination rsv pv vaccine phase ready important u two different perspective one side nextgeneration vaccine technology within respiratory box protein virus like particle vaccine importance vaccine potential better effective safe nonvlp vaccine basically expect see vaccine higher efficacy longer durability fact time better safety profile second important aspect combination rsv hmpv vaccine although number argue number rsv vaccine potation available market neither preventative therapeutic option hmpv maybe virus many even never heard tell rsv hmpv basically among leading cause severe respiratory infection look number hospitalization infection basically similar rate hmpv rsv flu therefore feel feel excited use vaccine one side accelerate bring patient soon possible side great strategic fit really build experience r well build therapeutic leverage serving patient risk respiratory disease end need mention dl still subject closingpascal soriot chief executive officer luisa second question rd spend said expect keep low percentage percentage revenue improvement come name committed achieving margin expansion midterm communicated quite time track remitted really leveraging critical mass product required sorry lot promotion scale term promotional effort look base look mean farxiga even potentially declining promotion manage large sga spend manage say actually deliver midterm ambition longterm ambition operating margin something define next couple year see progression pipeline quite honestly seen last two three year expansion pipeline number product pipeline pcsk course believe drive lot topline growth could anticipated say couple year ago depending pipeline shape decide percentage margin ambition said many time want clear focus absolute dollar value cash flow deliver saying compromise future progression operating margin beyond mids comprise percentage deliver top line absolute dollar value operating profit cash flow ultimate keep saying deliver value shareholder dollar percentage right really deliver even growth anticipated two year ago drive profit adjust next couple year based pipeline firm commitment absolute value deliver substantial growth top line also bottomline growth microphone thereeric le berrigaud stifel financial corp analyst eric berg stifel two question first aradhana coming back one comment capex capex anticipated grow maybe much think going forward oneyear sharp increase think capex staying around billion next year percentage revenue model maybe second question ruud sharon maybe next wave innovation biologics respiratory see one competition coming longacting il see interest tslp targeting also long acting also combining target astrazeneca next wave build existing franchisearadhana sarin chief financial officer sure thank question capex look last several year benchmark u peer actually underinvested capex substantially also opportunity invest forth look forward especially year given guidance specifically investing behind number product bringing forward right announced cell therapy facility rockwell susan talked whole cell therapy ambition requires upfront investment capex risk obviously investing api plant dublin also trying become selfsufficient relates api announced inhaled facility qingdao fulfill demand expect breast example come china addition investing erp system would say many many year invested number investment making behind pipeline seen recent transaction investment peer done become increasingly important selfreliant supply chain oftentimes see company able fulfill growth ambition underinvestment supply sort getting ahead curve pipeline new opportunitiespascal soriot chief executive officer one thing plant qingdo support growth ambition respiratory market china look copd china totally underdeveloped mean treatment disease extremely prevalent production smoking aging lot copd market totally underdeveloped today percent market share breast triple segment china market develops working hard expanding market develop local manufacturing enormous potential product like breast really decided make investmentruud dobber executive vice president president biopharmaceuticals quickly regarding let u say future biologics sharon comment science moment despite progress seen last year drug like inaudible also fact life still high unmet medical need remains still patient suffering multiple execution severe asthma segment well copd going bet new mode action cns clearly one example sure sharon say little bit also antitsip development quite spectacular inhaled biologic order help patient suffering severe disease new mode action hopefully unlock power medicine indication see think lot study next year asthma copd order generate evidence worksharon barr executive vice president biopharmaceuticals research development build really continue forward ruuds message proud following science thinking patient need create next wave therapeutic aware patient respiratory disease asthma copd first treated community progressed specialty care creating range therapeutic able meet need care provider also building science increasingly understand disease asthma building success fasenra aspire moving forward thinking tozorakimab effective tozorakimab differentiated therapeutic antiil hitting st rageegfr pathway able address inflammatory piece disease well mucus production remodeling think going powerful patient thinking patient accessing care moving prebiologic space inhaled tslip think novel mode delivery allow u broaden modality larger number patient well inhaled jak inhibitor oral flap inhibitor really expanding science prebiologic space thinking copd major unmet metal need worldwide building success breast tree thinking delivering inhaled tslip prebiologic space offering patient option well irak inhibitor evaluating midiparstat space offering patient number different opportunity address rare disease general practitioner also access biologics different mechanism moving specialty care hope answer questioneric le berrigaud stifel financial corp analyst il even physician seen le data sanofi inaudible phase already phase issue think getting phase year planning give morearadhana sarin chief financial officer know encourage data would like phase program look forward sharing phase date becomes available coming medical conferenceruud dobber executive vice president president biopharmaceuticals two big one ongoing one ntr also acute respiratory failure hopefully see data next season someone next year positive finger crossed first ntr complete new segment big unmet medical need second one clearly phase three trial copd space added additional arm high dose trial ongoing read next two yearspascal soriot chief executive officer maybe take last question ok andy gonzalo question gonzalo yougonzalo artiach abg sundal collier analyst hi could hear mepascal soriot chief executive officer yesgonzalo artiach abg sundal collier analyst hi gonzalo abg sundal collier couple question first one airsupra follows previous question audience big expected sale force commercial team airsupra current level awareness drug doctor today also preparing launch biggest challenge based experience year penetrate market one could expect quite conservative second question tagrisso seemed report today demand china hospital ordering dynamic could give u color much expected affect australian government rebate looking also beyond thank youruud dobber executive vice president president biopharmaceuticals try answer question concise way first field force going let u say give complete number substantial field u substantial two reason detailing allergy well pulmonologist well detailing large number primary care physician good news field force shared field force breast try economically savvy order make sure going top awareness used create substantial amount awareness awareness level allergist pulmonologists especially allergist first prescribers started soft way last quarter last quarter already trialists especially specialist level airsupra biggest change last question asking headwind biggest challenge biggest challenge happy three large commercial pbms listed airsupra multiple downstream pbms still need gain access nothing specific airsupra fact life yous environment working diligently market access team order create access equally going bid part course year welldave fredrickson executive vice president oncology business yes tagrisso within china fourth quarter hospital ordering dynamic seen last several year really hospital managing budget come end calendar year also fiscal year carry weight outlook fact think enter certainly continue face competition face nearly much competition adjuvant setting think important remind sizable egfr population within china also thoracic surgeon ability prescribe systemic therapy therefore relatively high adjuvant treatment rate adaura added nrdl discount think come year opportunity see growth really real demand side thing many fewer competitor playing within adjuvant space data think stand impressive australia rebate reclassification almost direct offset see zoladex established rest world beat tagrisso rest world beat mostly onetime event would say mostly carry year anticipate talking ever againpascal soriot chief executive officer thank dave thank much interest great question maybe message close meeting first one kind taking account question last today first one product sale still strong product sale product set grow mean growth product sale coherent guidance gave top line revenue clear message dependent collaboration revenue grow portfolio well geography well second message committed midterm operating margin course challenging said big portfolio invest growth get committed working toward making good progress saw margin expansion one slide continue direction third message maybe believe manage part reform mentioned know people speculated going big problem small headwind mean headwind headwind constantly one market another one product another beauty pipeline footprint geographically one product face headwind product pick remember product blockbuster status today one geography struggling bit another one better really model overall partly spent lot time team spent lot time working modeling incremental rebate deal first part compensated reduction free good substantial oncology medicine overall net effect certainly negative really totally manageable context total global sale growth rate experiencing finally importantly absolutely confident deliver strong longterm growth really want show hopefully convince rd day hope many join u beautiful disk tremendously talented team great job today huge number collaboration cambridge area really leading good productivity rd effort thank much thanks great question duration minutescall participantsandy barnettpascal soriot chief executive officeraradhana sarin chief financial officerdave fredrickson executive vice president oncology businesssusan galbraith executive vice president oncology research developmentruud dobber executive vice president president biopharmaceuticalssharon barr executive vice president biopharmaceuticals research developmentmarc dunoyer chief executive officer alexion chief strategy officer astrazenecajames gordon jpmorgan chase company analystemily field barclays analystmatt weston ubs analystandrew baum citi analystpeter welford jefferies analystmark purcell morgan stanley analystsimon baker redburn partner analysttim anderson wolfe research analystluisa hector berenberg capital market analystiskra reic executive vice president vaccine immune therapieseric le berrigaud stifel financial corp analystgonzalo artiach abg sundal collier analyst azn analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool recommends astrazeneca plc motley fool disclosure policy